埃克替尼联合胸腔镜治疗非小细胞肺癌的疗效观察

目的探讨埃克替尼片联合胸腔镜微创治疗对非小细胞肺癌患者的生活质量及血管内皮生长因子C(VEGF-C)的影响。方法选取2018年12月至2020年6月间盘锦辽油宝石花医院收治的82例非小细胞肺癌患者。采用随机数表法将患者分成对照组和观察组,每组41例。对照组患者采用胸腔镜微创治疗方式,观察组患者采用埃克替尼片联合胸腔镜微创治疗方式。观察比较两组患者的临床治疗效果、VEGF-C水平、生活质量以及不良反应发生情况。结果观察组患者的疾病控制率为73.2%,高于对照组的48.8%,差异有统计学意义(P<0.05)。观察组患者治疗后的VEGF-C水平低于对照组,差异有统计学意义(P<0.05)。观察组治疗后的生活质量评分高于对照组,差异有统计学意义(P<0.05)。两组患者不良反应比较,差异无统计学意义(P>0.05)。结论埃克替尼片联合胸腔镜微创治疗非小细胞肺癌患者,能够有效降低VEGF-C水平,提高患者的疾病控制率和生活质量,并且安全性良好。

Efficacy of icotinib combined with video assisted thoracoscopic surgery for non-small cell lung cancer

Objective To explore the effects of icotinib tablets combined with video-assisted thoracoscopic surgery(VATS)on quality of life and vascular endothelial growth factor-C(VEGF-C)in patients with non-small cell lung cancer(NSCLC).Methods From December 2018 to June 2020,82 patients with NSCLC were selected at Liaoyou Baoshihua Hospital and were randomly divided into an observation group and a control group with 41 patients in each group.The observation group received icotinib plus VATS and the control group received VATS.The clinical therapeutic efficacy,VEGF-C level,quality of life and adverse reactions were compared between the two groups.Results The disease control rate was 73.2%in the observation group which was higher than 48.8%of the control group(P<0.05).The level of VEGF-C was significantly lower in the observation group than in the control group(P<0.05).After treatment,quality of life was significantly higher in the observation group than in the control group(P<0.05).There was no significant difference between in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Icotinib combined with VATS can effectively reduce the level of VEGF-C,improve the disease control rate and quality of life in patients with NSCLC with good safety.